Skip to main content

Table 2 EGFR exon 19 deletions/substitution

From: Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients

#

Sex

Ethnicity

Smoking Status

Source Tissue

Response1

I

  

K

  

E

  

L

  

R

  

E

  

A

  

T

  

S

  

P

  

K

a.a.

      

T

C

A

A

G

G

A

A

T

T

A

A

G

A

G

A

A

G

C

A

A

C

A

T

C

T

C

C

G

A

A

CDS

11

F

Asian

Unk.

Lung

PR

T

C

A

A

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

A

A

C

A

T

C

T

C

C

G

A

A

Het*

22

M

Asian

N

Lymph Node

PD

T

C

A

A

G

G

A

A

-

-

-

-

-

C

-

-

-

-

-

-

-

C

A

T

C

T

C

C

G

A

A

Het

25

F

Asian

N

Lung

PD

T

C

A

A

G

G

A

A

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

T

C

T

C

C

G

A

A

Del

66

F

Asian

N

Lung

PR

T

C

A

A

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

A

A

C

A

T

C

T

C

C

G

A

A

Het*

  1. Deletions of L747-A750 were detected in EGFR exon 19. All samples were classified as adenocarcinoma based on histology. Deleted bases are indicated by "-". In the case of patient #22, thirteen deleted bases were replaced by a single 'C' thereby retaining the reading frame. In all cases, the ATP-binding residue K745 was retained. In the case of patients #11 and #66, a synonymous codon change results from the deletion (AAG > AAA) and the K745 ATP-binding residue is unchanged.
  2. * = no mutations detected in normal tissue remaining after microdissection.
  3. 1 = response as measured radiographically and defined by SWOG modification of the WHO criteria.
  4. PD = progressive disease, SD = stable disease, PR = partial response, Unk. = Unknown